Table 3.

SPARCC MRI 23 DVU scores for spinal inflammation at baseline and at 12 weeks after randomization to either placebo (n = 16) or infliximab 3 mg/kg (n = 16) in patients with AS.

ReaderTreatmentBaseline mean (SD) median (25/75 IQ) 95% CI rangeWeek 12 mean (SD) median (25/75 IQ) 95% CI rangeChange mean (SD) median (25/75 IQ) 95% CI rangep
BPlacebo24.13 (33.83)23.56 (34.11)−0.56 (6.51)0.0009
5.5 (2.0/55.0)6.5 (2.0/50.75)0.0 (0.0/0.75)
6.10, 42.155.39, 41.74−4.03, 2.91
0.0–94.00.0–97.0−23 to 10
BInfliximab16.56 (21.98)4.56 (9.71)−12.0 (16.26)
9.0 (0.0/24.0)0.0 (0.0/6.0)−7.0 (−18.5/0.0)
4.85, 28.27−0.61, 9.74−20.67, −3.33
0.0–70.00.0–37.0−54.0 to 0.0
CPlacebo23.88 (26.85)24.44 (30.43)0.56 (5.81)0.0016
12.50 (4.25/41.75)9.0 (3.25/39.0)−0.50 (−2.75/3.25)
9.57, 38.188.22, 40.65−2.53, 3.66
0.0–90.00.0–94.0−10.0 to 15
CInfliximab22.50 (26.09)7.69 (13.05)−14.81 (14.74)
11.50 (1.75/35.5)1.50 (0.0/9.25)−10.0 (−27.25/−0.25)
8.60, 36.400.74, 14.64−22.67, −6.96
0.0–77.00.0–39.0−50.0 to 0.0
  • SPARCC: Spondyloarthritis Research Consortium of Canada; MRI: magnetic resonance imaging; DVU: discovertebral units; AS: ankylosing spondylitis. IQ: interquartile.